



Department
of Health &
Social Care

UK Clinical Research Delivery Key Performance Indicators Report

Report date: 03 September 2025

NIHR RDN data cut date: 30 August 2025

MHRA data cut date: 20 August 2025

For circulation

Purpose

The Government is committed to maintaining new system-wide UK Clinical Research Delivery Key Performance Indicators (UK KPIs) to drive short-medium term progress towards delivering our vision for clinical research. We will also continue to monitor and publish a range of data to support the implementation of these indicators, understand their impact including on non-commercial studies, and address any unintended consequences. Building on our experience in delivering Research Reset, we will use these data to inform the development of impactful incentives and consequences to help drive achievement of the UK KPIs.

This report is produced monthly by DHSC on behalf of the UK research delivery system. It draws together data on the progress towards all the published UK KPIs providing transparent updates on progress towards our goals over time. The indicators apply at a UK system-wide level and implementation will be overseen by DHSC, the Devolved Administrations (DAs) and the NHS. The UK KPIs, and other commitments set out in the Full Government Response to the Lord O'Shaughnessy Review, are intended to provide clear and measurable goals from the time of publication to spring/summer 2025. Progress against these goals, delivery of a significant programme of activity to achieve them and wider work to improve the availability of data about the delivery of research are due to be completed by 2025, at which point a revised set of UK KPIs will be developed and published.

We are committed to maintaining a rich and balanced portfolio of early and late phase studies in rare and common diseases, ranging from complex, intensive studies in small, highly targeted populations to pragmatic population health research in large cohorts, using a range of methodologies and methods as appropriate to the research questions.

This report categorises data into three distinct groups:

- Commercial contract studies are studies sponsored and fully funded by the life sciences industry.
- Commercial collaborative studies are studies typically funded, wholly or in part, by the life sciences industry and sponsored by a combination of life sciences industry and non-commercial organisations. This category has previously been included in non-commercial figures but is being disaggregated going forward to better represent the breadth of commercial studies. Commercial collaborative studies are supported in the same way as other non-commercial studies, including provision of support costs and excess treatment costs via the National Institute for Health and Care Research (NIHR) Research Delivery Network (RDN) and the NHS.
- Non-commercial studies are studies sponsored and wholly funded by one or more non-commercial organisations, including medical research charities, universities and public funders, such as NIHR and UK Research and Innovation (UKRI).

Data source

All UK KPIs measure UK performance for studies on the NIHR RDN Portfolio¹, except for regulatory approvals (1) which will measure timelines for combined review and National Contract Value Review (4) which includes all commercial contract studies taking place in NHS trusts.

Note on methodology

From December 2023 onwards, all studies from the NIHR RDN's Central Portfolio Management System (CPMS) are included in charts and tables, regardless of UK lead country or participating countries unless otherwise stated. In addition, the methodology used to determine study progress

¹ The Clinical Research Network (CRN) is transitioning throughout 2024/2025 to the RDN. From October 2024, the CRN will be known as the RDN.

towards planned milestones has changed to use UK recruitment and UK target² with the exception of measure 5 (time and target).

UK Key Performance Indicators Overview

With the exception of combined review (1) and National Contract Value Review (4), all UK KPIs measure performance for studies on the NIHR RDN Portfolio. The indicators apply at a UK system-wide level and implementation will be overseen by DHSC, the devolved administrations (DAs) and the NHS.

		UK Key Performance Indicator	Target	Timeline for delivery	Baseline³	August 2025 Report
1	All ⁴	Proportion of studies receiving a combined review decision within 60 days, measured from IRAS submission to combined MHRA and REC regulatory decision	99%	Maintain target for all new fully compliant initial applications received from 1 September 2023	100%	97%
2	C ⁵	Proportion of studies open to recruitment within 60 days of HRA approval letter or equivalent process used by the Devolved Administrations	90%	November 2024	39%	15% ⁶
3	C	Proportion of studies recruiting first participant within 30 days of sites opening to recruitment, except where this is not expected in the study milestone plan (for example, rare diseases studies)	90%	November 2024	25%	17% ⁶
4	C	Proportion of NHS trusts in England who accept the local price generated as part of the NCVR process for late-phase studies without further negotiation following agreement of the resource required by the lead site	100%	December 2023	79%	100%
5	All	Proportion of open studies on track, delivering to time and target	80%	June 2023	80%	83% ⁷

² UK target for commercial studies does not include private sites.

³ Some measures are new and therefore the baseline was established in different months.

⁴ All indicates a measure that applies to all studies.

⁵ 'C' indicates that it applies to commercial contract studies only.

⁶ There can be a lag between activity and data being recorded in the central system, therefore, previous months' data may be updated retrospectively.

⁷ Based on recruitment in England and England target.

6	All	Recruitment to all studies is maintained at high levels when compared to pre-pandemic baseline of 61,000 ^{8,9}	70,000 or more per month ¹⁰	Ongoing	70,000	85,011 ¹⁰
7	C	Recruitment to all commercial studies to be monitored in support of the ambition to double and double again from the pre-pandemic baseline of 3,200 ^{8,9}	Reported per month ¹⁰	Ongoing	3,200	3,836 ¹⁰

Other Measures

We will continue to monitor and publish a range of data in addition to the UK KPIs to support their implementation, understand their impact including on non-commercial studies, and address any unintended consequences.

		Measure	Purpose	Baseline	August 2025 Report
8	All	Proportion of studies on the NIHR RDN Portfolio which are open to recruitment is ≥80%	A proportion of studies on the portfolio will be in set-up prior to opening. To enable all studies to progress to planned timelines, we aim for no more than 20% of studies to be in set-up	80%	82%

		Measure	Purpose	August 2025 registrations	Cumulative total registrations
9		Be Part of Research monthly registrations	We have set a goal of 1 million people to be signed up to Be Part of Research by April 2025	17,679	642,158

⁸ Average per month in England only from 2015 to 2020.

⁹ Data on trial phase to be provided subsequent to implementation of digital infrastructure.

¹⁰ Rolling average across the previous 12 months.

Achieving globally competitive timelines

1. Proportion of studies receiving a combined review decision within 60 days, measured from IRAS submission to combined MHRA and REC regulatory decision										Baseline	
Study type: All studies		Measure: ≥99%		Timeline: Maintain target for all new fully compliant initial applications received from 1 September 2023						100%	
Sep 2024	Oct 2024	Nov 2024	Dec 2024	Jan 2025	Feb 2025	Mar 2025	Apr 2025	May 2025	June 2025	July 2025	Aug 2025
95%	86%	99%	98%	96%	92%	100%	98%	100%	96%	98%	97%

For applications received with an effective date of 1 September 2023 onwards, 76 Initial Clinical Trial Authorisation applications were approved via the combined review process, with outcomes communicated in July 2025. **Ninety-seven percent** (74/76) of applications were approved within 60 days from the application received effective date.

The Medicines and Healthcare products Regulatory Agency (MHRA) and Research Ethics Committee (REC) issued the joint outcome from the initial combined assessment on an average of 28.03 days from the application received effective date.

On receipt of the sponsor's response to the list of questions raised by the MHRA and REC, the MHRA and REC issued the joint final outcome in an average of 12.73 days.

The total average time to approve an Initial Clinical Trial Authorisation application, including the response to questions raised, via the combined review process was 40.77 days from the application received effective date.

It should be noted that the sponsor can choose to attend a REC meeting that is not the first available in the combined review system and therefore, the combined review assessment time does not start until 2 weeks prior to the REC meeting (i.e. the Integrated Research Application System (IRAS) submission date is different from the application received effective date). It should also be noted that the sponsor can request for extensions to the grounds for non-acceptance response deadline. This is granted and will extend the end-to-end timeline from IRAS submission to final approvals. The indicator measures the time that the MHRA and REC spent assessing the application only.

Other relevant reports:

MHRA also publish performance data for assessment of clinical trials and established medicines: <https://www.gov.uk/government/publications/mhra-performance-data>

2. Proportion of commercial contract studies open to recruitment within 60 days of HRA approval letter or equivalent process used by the Devolved Administrations		
Study type: Commercial contract studies	Measure: ≥90%	Timeline: Achieve by November 2024

Month	Number of studies that received HRA approval	Open to recruitment	Opened to recruitment within 60 days	Opened to recruitment after 60 days	Not yet open to recruitment
December 2023	46	45	13 (28%)	32 (70%)	1 (2%)
January 2024	48	45	12 (25%)	33 (69%)	3 (6%)
February 2024	46	43	11 (24%)	32 (70%)	3 (7%)
March 2024	54	53	14 (26%)	39 (72%)	1 (2%)
April 2024	39	39	7 (18%)	32 (82%)	0 (0%)
May 2024	64	58	12 (19%)	46 (72%)	6 (9%)
June 2024	47	45	8 (17%)	37 (79%)	2 (4%)
July 2024	48	47	11 (23%)	36 (75%)	1 (2%)
August 2024	53	49	14 (26%)	35 (66%)	4 (8%)
September 2024	44	42	13 (30%)	29 (66%)	2 (5%)
October 2024	50	46	18 (36%)	28 (56%)	4 (8%)
November 2024	52	50	20 (38%)	30 (58%)	2 (4%)
December 2024	48	41	16 (33%)	25 (52%)	7 (15%)
January 2025	41	28	14 (34%)	14 (34%)	13 (32%)
February 2025	40	26	10 (25%)	16 (40%)	14 (35%)
March 2025	49	26	14 (29%)	12 (24%)	23 (47%)
April 2025	49	24	8 (16%)	16 (33%)	25 (51%)
May 2025	36	10	8 (22%)	2 (6%)	26 (72%)
June 2025	27	4	4 (15%)	0 (0%)	23 (85%)
July 2025	15	0	This will be calculated when 60 days have elapsed.		15
August 2025	4	1	This will be calculated when 60 days have elapsed.		3

This is a new measure. This section presents data from the NIHR RDN's Central Portfolio Management System (CPMS). It measures the proportion of commercial contract studies which have received HRA approval, or its equivalent in the DAs, since 1 December 2023 and are open to recruitment within 60 days. The target is 90%, with an aim to achieve this by November 2024.

There is a latency or lag between activity and data being recorded in the central system, therefore, previous months' data may be updated retrospectively. Changes in performance for individual recent months should not be taken as an indication of overall trend in performance.

3. Proportion of commercial contract studies recruiting first participant within 30 days of sites opening to recruitment, except where this is not expected in the study milestone plan (for example, rare diseases studies)		
Study type: Commercial contract studies	Measure: ≥90%	Timeline: Achieve by November 2024

Month	Number of studies open to recruitment	Recruited first participant	Recruited first participant within 30 days	Recruited first participant after 30 days	Not yet recruited first participant
December 2023	19	17	8 (42%)	9 (47%)	2 (11%)
January 2024	25	20	12 (48%)	8 (32%)	5 (20%)
February 2024	24	20	10 (42%)	10 (42%)	4 (17%)
March 2024	19	18	12 (63%)	6 (32%)	1 (5%)
April 2024	27	21	8 (30%)	13 (48%)	6 (22%)
May 2024	13	9	6 (46%)	3 (23%)	4 (31%)
June 2024	21	19	10 (48%)	9 (43%)	2 (10%)
July 2024	31	28	12 (39%)	16 (52%)	3 (10%)
August 2024	18	17	8 (44%)	9 (50%)	1 (6%)
September 2024	22	18	8 (36%)	10 (45%)	4 (18%)
October 2024	32	28	13 (41%)	15 (47%)	4 (13%)
November 2024	25	19	10 (40%)	9 (36%)	6 (24%)
December 2024	20	16	6 (30%)	10 (50%)	4 (20%)
January 2025	21	13	9 (43%)	4 (19%)	8 (38%)
February 2025	30	22	8 (27%)	14 (47%)	8 (27%)
March 2025	23	19	8 (35%)	11 (48%)	4 (17%)
April 2025	18	11	4 (22%)	7 (39%)	7 (39%)
May 2025	17	9	5 (29%)	4 (24%)	8 (47%)
June 2025	19	5	4 (21%)	1 (5%)	14 (74%)
July 2025	18	4	3 (17%)	1 (6%)	14 (78%)
August 2025	4	1	This will be calculated when 30 days have elapsed.		3

This is a new measure. This section presents data from the NIHR RDN's Central Portfolio Management System (CPMS). It measures the proportion of commercial contract studies which have recruited their first participant within 30 days of opening to recruitment.

There is a latency or lag between activity and data being recorded in the central system, therefore, previous months' data may be updated retrospectively. Changes in performance for individual recent months should not be taken as an indication of overall trend in performance.

Contracting and delivery

4. Proportion of NHS trusts in England who accept the local price generated as part of the NCVR process for late-phase commercial contract studies without further negotiation following agreement of the resource required by the lead site			Baseline	December 2023
Study type: Commercial Contract Studies	Measure: 100%	Timeline: Achieve by December 2023	79%	100%

This section presents data from the NIHR RDN and is the number of organisations that have agreed to accept outputs of the negotiated agreement reached between the company or Clinical Research Organisation (CRO) and the single National Contract Value Review (NCVR).


NCVR is now mandatory for all commercial contract studies, excluding those taking place in primary care. There is a voluntary NCVR scheme for GP practices.

Between October 2023 and October 2024, NCVR was mandatory for all commercial contract studies, excluding Advanced Therapeutic Medicinal Product (ATMP) and early phase studies, taking place in secondary, specialist and mental health trusts.

5. Proportion of open studies on track, delivering to time and target											
Study type: All studies				Measure: ≥80%			Timeline: Maintain ≥80% achieved in June 2023				
Sep 2024	Oct 2024	Nov 2024	Dec 2024	Jan 2025	Feb 2025	Mar 2025	Apr 2025	May 2025	Jun 2025	Jul 2025	Aug 2025
83%	83%	83%	84%	83%	84%	83%	84%	83%	82%	84%	83%


This section presents data from the NIHR RDN’s Central Portfolio Management System (CPMS) combined with self-reported data provided by sponsors through the Sponsor Engagement Tool. This approach recognises that sponsors and funders have the most accurate view of a study’s progress towards its planned milestones and enables us to focus our efforts more precisely on the studies where progress is not being made. We aim for 80% of all open studies on the NIHR RDN Portfolio to be on track towards delivering to time and target.

Chart 5a: Proportion of open studies delivering to time and target by month



■ On track as per CPMS or validated 'On track' by sponsor
 ■ Off track

Chart 5b: Proportion of open studies delivering to time and target by current month and study type



 On track as per CPMS or validated 'On track' by sponsor  Off track


Levels of recruitment

6. Recruitment to all studies is maintained at high levels when compared to pre-pandemic baseline of 61,000											
Study type: All studies		Measure: 70,000 or more per month (reported per month, as a rolling average across the previous 12 months)				Timeline: Maintain high levels of recruitment compared to pre-pandemic baseline of 61,000					
Sep 2024	Oct 2024	Nov 2024	Dec 2024	Jan 2025	Feb 2025	Mar 2025	Apr 2025	May 2025	Jun 2025	Jul 2025	Aug 2025
89,678	89,075	89,648	90,955	90,624	90,737	90,835	92,821	88,178	87,272	87,122	85,011

This section presents data from the NIHR RDN's Central Portfolio Management System (CPMS). Overall recruitment is an indication of a well-functioning research delivery system. There is currently no target for overall recruitment as performance remains high compared to the pre-pandemic baseline of c.61,000¹¹. A benchmark of an average of 70,000 or more recruits per month enables us to monitor overall levels of activity.

There is a latency or lag between activity and data being recorded in the central system, therefore, previous months' data are expected to change.¹² Drops in performance for individual recent months should not be taken as an indication of overall trend in performance. It should be further noted that we would expect recruitment numbers to be lower over the holiday period (July/August and December).

Chart 6a: Recruitment by month – all studies



¹¹ Average per month in England only from 2015 to 2020.

¹² The figures reported in table 6 are the recruitment figures as reported by NIHR at the time of the data cut and are not updated retrospectively. Chart 6a is updated retrospectively as the central data system is updated.

7. Recruitment to all commercial studies to be monitored in support of the ambition to double and double again from the pre-pandemic baseline of 3,200											
Study type: Commercial contract studies		Measure: Reported per month, as a rolling average across the previous 12 months				Timeline: Monitor in support of the ambition to double and double again from the pre-pandemic baseline of 3,200					
Sep 2024	Oct 2024	Nov 2024	Dec 2024	Jan 2025	Feb 2025	Mar 2025	Apr 2025	May 2025	Jun 2025	Jul 2025	Aug 2025
13,291	12,856	11,938	10,876	9,130	8,750	7,932	7,016	5,830	5,209	4,201	3,836

7b. Recruitment to commercial collaborative studies											
Study type: Commercial collaborative studies		Measure: Reported per month, as a rolling average across the previous 12 months				Timeline: No timeline					
Sep 2024	Oct 2024	Nov 2024	Dec 2024	Jan 2025	Feb 2025	Mar 2025	Apr 2025	May 2025	Jun 2025	Jul 2025	Aug 2025
9,983	10,079	10,209	9,970	9,764	9,798	9,460	9,116	8,603	8,112	7,650	8,139

This section presents data on two sub-sets of the overall recruitment figures presented in section 6, specifically focusing on recruitment to commercial contract studies (sponsored and fully funded by the life sciences industry) and recruitment to commercial collaborative studies (typically funded, wholly or in part, by the life sciences industry and sponsored by a combination of life sciences industry and non-commercial organisations).

Levels of recruitment to commercial contract research can be significantly affected by a small number of studies with very high recruitment targets. While we continue to aim to attract high recruiting studies to the UK, we are committed to a rich and diverse portfolio, which meets both industry and patient needs, and we recognise many commercial contract studies recruit relatively small numbers of participants. To address this inherent variability, our target reflects average monthly recruitment figures over the five years prior to the pandemic, and, as with recruitment to all studies, current figures represent a rolling 12-month average.

As in section 6, there is a latency or lag between activity and data being recorded in the central system, therefore, previous month's data are expected to change.¹³ Drops in performance for individual recent months should not be taken as an indication of overall trend in performance. It should be further noted that we would expect recruitment numbers to be lower over the holiday period (July/August and December).

¹³ The figures reported in tables 7 and 7b are the recruitment figures as reported by NIHR at the time of the data cut and are not updated retrospectively. Charts 7a to 7d are updated retrospectively as the central data system is updated.

The following charts break down overall recruitment by study type over the last 12 months or the period running from five years before the pandemic through to the current month.

These categorises studies into three distinct groups:

- Commercial contract studies are studies sponsored and fully funded by the life sciences industry.
- Commercial collaborative studies are studies typically funded, wholly or in part, by the life sciences industry and sponsored by a combination of life sciences industry and non-commercial organisations. This category has previously been included in non-commercial figures but is being disaggregated going forward to better represent the breadth of commercial studies. Commercial collaborative studies are supported in the same way as other non-commercial studies, including the provision of support costs and excess treatment costs via the NIHR RDN and the NHS.
- Non-commercial studies are studies sponsored and wholly funded by one or more non-commercial organisations, including medical research charities, universities and public funders, such as NIHR and UK Research and Innovation (UKRI).

We are committed to maintaining a rich and balanced portfolio of early and late phase studies in rare and common diseases, ranging from complex, intensive studies in small, highly targeted populations to pragmatic population health research in large cohorts, using a range of methodologies and methods as appropriate to the research questions.

Chart 7a: Recruitment by month and study type over the last 12 months




Chart 7b: Commercial contract recruitment since April 2015




Chart 7c: Commercial collaborative recruitment since April 2015





Chart 7d: Non-commercial recruitment since April 2015 (excluding commercial collaborative)



Other measures

8. Proportion of studies on the NIHR RDN Portfolio which are open to recruitment or suspended											
Study type: All studies		Measure: No target		We monitor the proportion of open or suspended studies and expect this to be c.80% open or suspended / c.20% in set up as a sign of a healthy pipeline of studies.							
Sep 2024	Oct 2024	Nov 2024	Dec 2024	Jan 2025	Feb 2025	Mar 2025	Apr 2025	May 2025	Jun 2025	Jul 2025	Aug 2025
82%	83%	82%	82%	82%	83%	83%	83%	83%	82%	83%	82%

This section presents data from the NIHR RDN’s Central Portfolio Management System (CPMS). The active portfolio consists of studies defined as either ‘open or suspended’ or ‘in set up’.

We have 5,618 studies on the portfolio. **82% of studies are classed as open or suspended.**

Chart 8a: Proportion of studies that are open or suspended (last 12 months)




Chart 8b: Proportion of studies that are open or suspended by current month and study type




Table 8a: Number of active studies on the NIHR RDN Portfolio, by study type and status

Study type	In set-up	Open	Suspended	Total	% Total
Commercial contract	489	1,141	42	1,672	30%
Commercial collaborative	54	388	18	460	8%
Non-commercial	469	2,900	117	3,486	62%
Total	1,012	4,429	177	5,618	100%

Table 8b: Number of new studies added to the NIHR RDN Portfolio, last 12 completed months by study type and month

Month	Commercial contract	Commercial collaborative	Non-commercial	Total
Aug 2024	41	7	64	112
Sep 2024	46	3	90	139
Oct 2024	65	12	84	161
Nov 2024	65	8	83	156
Dec 2024	44	3	68	115
Jan 2025	50	10	90	150
Feb 2025	45	13	76	134
Mar 2025	49	14	79	142
Apr 2025	43	3	75	121
May 2025	59	10	89	158
Jun 2025	68	6	83	157
Jul 2025	79	9	108	196
Monthly Average¹⁴	55	8	82	145

¹⁴ Table 8b now contains correct monthly average figures, correcting a previous error.

9. Be Part of Research monthly registrations	
We have set a goal of 1 million people to be signed up to Be Part of Research by April 2025	
August 2025 registrations	Cumulative total registrations
17,679	642,158

Chart 9a: Be Part of Research cumulative registrations



Table 9a: Be Part of Research registrations by month¹⁵

Month and Year	Total monthly registrations	Cumulative total registrations
Jul 2022	60	60
Aug 2022	8,630	8,690
Sep 2022	16,925	25,615
Oct 2022	402	26,017
Nov 2022	1,359	27,376
Dec 2022	87	27,463
Jan 2023	1,020	28,483
Feb 2023	20,203	48,686
Mar 2023	16,354	65,040
Apr 2023	46,911	111,951
May 2023	45,093	157,044
Jun 2023	36,981	194,025
Jul 2023	39,727	233,752
Aug 2023	39,151	272,903
Sep 2023	39,102	312,005
Oct 2023	32,809	344,814
Nov 2023	30,128	374,942
Dec 2023	22,054	396,996
Jan 2024	15,744	412,740
Feb 2024	16,958	429,698
Mar 2024	25,376	455,074
Apr 2024	23,615	478,689
May 2024	20,710	499,399
June 2024	18,785	518,184
July 2024	19,790	537,974
Aug 2024	16,051	554,025
Sep 2024	10,265	564,290
Oct 2024	10,799	575,089
Nov 2024	4,234	579,323
Dec 2024	3,617	582,940
Jan 2025	4,924	587,864
Feb 2025	4,113	591,977
Mar 2025	4,280	596,257
April 2025	4,151	600,408
May 2025	4,058	604,466
Jun 2025	5,923	610,389
Jul 2025	14,090	624,479
Aug 2025	17,679	642,158

END OF REPORT

¹⁵ Please note that a data correction has been made to previous months data where completed registrations were being counted in both the month of registration commencement and month of registration completion.

Annex A: UK clinical research recruitment to interventional and observational studies

Report date: 03 September 2025

NIHR RDN Data cut date: 30 August 2025

For circulation

Overview

Charts 10a to 10f show the number of participants recruited each month into studies held on the National Institute for Health and Care Research (NIHR) Research Delivery Network's (RDN) Central Portfolio Management System (CPMS).

The data in each of these charts are broken down into interventional and observational studies:

- **Interventional studies** are studies in which participants are assigned to receive one or more interventions (or no intervention for control) so that researchers can evaluate their effects on biomedical or health-related outcomes. The aim is to find out if a new intervention is suitable for people. Participants may receive diagnostic, therapeutic, or other types of interventions.
- **Observational studies** are studies in which the investigator observes without manipulation or intervention. These studies do not involve a new intervention but aim to find out information by observing the people taking part and seeing what happens in different situations.

As with the main UK Clinical Research Delivery Key Performance Indicators Report, the data are divided into three distinct study types:

- **Commercial contract studies** are studies sponsored and fully funded by the life sciences industry.
- **Commercial collaborative studies** are studies typically funded, wholly or in part, by the life sciences industry and sponsored by a combination of life sciences industry and non-commercial organisations. This category has previously been included in non-commercial figures but is being disaggregated going forward to better represent the breadth of commercial studies. Commercial collaborative studies are supported in the same way as other non-commercial studies, including the provision of support costs and excess treatment costs via the NIHR RDN and the NHS.
- **Non-commercial studies** are studies sponsored and wholly funded by one or more non-commercial organisations, including medical research charities, universities and public funders, such as NIHR and UK Research and Innovation (UKRI).

There is often a lag between activity taking place at a study site and data being recorded in the system; therefore, previous months' data may be updated retrospectively. Changes in recruitment for individual recent months should not be taken as an indication of overall trend in recruitment. It should be further noted that we would expect recruitment numbers to be lower over the holiday period (July/August and December).

Chart 10a: Recruitment into commercial contract studies over the last 12 months broken down by interventional and observational studies




Chart 10b: Recruitment into commercial contract studies since April 2015 broken down by interventional and observational studies




Chart 10c: Recruitment into commercial collaborative studies over the last 12 months broken down by interventional and observational studies




Chart 10d: Recruitment into commercial collaborative studies since April 2015 broken down by interventional and observational studies




Chart 10e: Recruitment into non-commercial studies over the last 12 months broken down by interventional and observational studies




Chart 10f: Recruitment into non-commercial studies since April 2015 broken down by interventional and observational studies

